PFIZER-BIONTECH COVID-19 VACCINATION SCHEDULE AND DOSING FOR MODERATELY TO SEVERELY IMMUNOCOMPROMISED POPULATIONS

**Pfizer-BioNTech**

**Ages 6 months–4 years**
- **dose/injection volume** (dilute before use)
- **Primary Dose:** Maroon Cap

**Dose 1**
- PRIMARY
- 3 µg/0.2 mL
- In 3 weeks

**Dose 2**
- PRIMARY
- 3 µg/0.2 mL
- In at least 8 weeks

**Dose 3**
- PRIMARY
- 3 µg/0.2 mL
- In at least 8 weeks

**Pfizer-BioNTech**

**5 year olds ONLY**
- **dose/injection volume** (dilute before use)
- **Primary/Booster Dose:** Pfizer Orange Cap

**Dose 1**
- PRIMARY
- 10 µg/0.2 mL
- In 3 weeks

**Dose 2**
- PRIMARY
- 10 µg/0.2 mL
- In at least 4 weeks

**Dose 3**
- PRIMARY
- 10 µg/0.2 mL
- In at least 2 months

**Booster**
- BIVALENT
- 10 µg/0.2 mL

**Pfizer-BioNTech**

**Ages 6 years–11 years**
- **dose/injection volume** (dilute before use)
- **Primary Dose:** Pfizer Orange Cap
- **Bivalent Booster:** Pfizer Orange Cap or Moderna Dark Blue Cap (gray label)

**Dose 1**
- PRIMARY
- 10 µg/0.2 mL
- In 3 weeks

**Dose 2**
- PRIMARY
- 10 µg/0.2 mL
- In at least 4 weeks

**Dose 3**
- PRIMARY
- 10 µg/0.2 mL
- In at least 2 months

**Booster**
- BIVALENT
- 10 µg/0.2 mL

**Pfizer-BioNTech**

**Ages 12 years and older**
- **dose/injection volume** (Do NOT dilute before use)
- **Primary Dose:** Gray Cap
- **Bivalent Booster:** Pfizer Gray Cap (gray label) or Moderna Dark Blue Cap (gray label)

**Dose 1**
- PRIMARY
- 30 µg/0.3 mL
- In 3 weeks

**Dose 2**
- PRIMARY
- 30 µg/0.3 mL
- In at least 4 weeks

**Dose 3**
- PRIMARY
- 30 µg/0.3 mL
- In at least 2 months

**Booster**
- BIVALENT
- Pfizer: 10 µg/0.2 mL
- Moderna: 25 µg/0.25 mL

Funding for this project was made possible by the Office of Disease Control, through the Illinois Department of Public Health.

illinoisvaccinates.com

*Complete the primary series with same product. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.*

†Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years. Source: [CDC](https://www.cdc.gov).